Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frusemide pharmacokinetics in heart failure and pulmonary hypertension
ACTRN12614000461695Phase 4Recruiting
- Sponsor
- Flinders University
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of furosemide in heart failure (HF) and pulmonary hypertension (PH) (2 cohorts), sponsored by Flinders University. Primary endpoints: Change in blood and urine concentration-time profiles after oral frusemide in decompensated and compensated congestive heart failure and Change in blood and urine concentration-time profiles after intravenous frusemide in decompensated and compensated congestive heart failure. Started May 2014; status: recruiting.
02
Drugs
furosemide
03
Conditions
heart failure (HF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on ACTRN12614000461695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000461695.